What this study is
CHIIME is a study of people who have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). People who do not have this condition will also be enrolled. Volunteers will be observed and sampled over time to identify the long-terms biological drivers and impact of their condition. The overall goal is to understand the biological and physiological mechanisms that are driving this condition.
Study details
- Sponsor
- University of California, San Francisco
- Conditions
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Enrolling
- 200 people
- Starts
- 2026-01-01
- Est. completion
- 2030-09
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Willing and able to provide written informed consent
- At least 18 years of age
- Either: (1) a reported diagnosis of ME/CFS or (2) no history of ME/CFS or other infection-associated chronic conditions (healthy control)
You can't join if
- Self reported or documented chronic anemia with hemoglobin <9 g/dL
- Known HIV, hepatitis B, or hepatitis C infection
- Diagnosis of an infection-associated chronic condition other than ME/CFS or Long COVID (e.g. chronic Lyme disease, post-Ebola syndrome, etc.)
- Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent
- Active drug or alcohol use or dependence that, in the opinion of the PI, would interfere with adherence to study requirements or to give informed consent
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openZuckerberg San Francisco General Hospital
San Francisco, California, United States
Recruiting
Study team
Sponsor
University of California, San Francisco
Study ID 24-43260
Principal investigator
Michael J. Peluso
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.